Evidence of hypoglycemic, lipid-lowering and hepatoprotective effects of the Bixin and Bixin: β-CD inclusion compound in high-fat-fed obese mice

• Published in: Biomedicine & pharmacotherapy 2018-10, Vol.106, p.363-372
• Main Authors: Pinzón-García, Ana Delia, Orellano, Laura Alejandra Ariza, de Lazari, Marcela Guimarães Takahashi, Campos, Paula Peixoto, Cortes, Maria Esperanza, Sinisterra, Ruben Dario
• Format: Article
• Language: English
• Subjects: 3T3-L1 Cells; Adipocytes - drug effects; Adipocytes - metabolism; Adipocytes - pathology; Adiposity - drug effects; Animals; beta-Cyclodextrins - pharmacology; Biomarkers - blood; Bixin; Blood Glucose - drug effects; Blood Glucose - metabolism; Carotenoids - pharmacology; Diabetes type II; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver - blood; Fatty Liver - etiology; Fatty Liver - pathology; Fatty Liver - prevention & control; Glucose Metabolism Disorders - blood; Glucose Metabolism Disorders - etiology; Glucose Metabolism Disorders - prevention & control; Hypoglycemic Agents - pharmacology; Hypolipidemic Agents - pharmacology; Inclusion compound; Lipids - blood; Liver - drug effects; Liver - metabolism; Liver - pathology; Male; Mice; Mice, Inbred C57BL; Obesity; Obesity - blood; Obesity - drug therapy; Obesity - etiology; Obesity - pathology; Steatosis; Time Factors
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2018.06.144

[Display omitted] •Bixin and Bix/βCD behave as assisting agents in the glucose uptake.•Adiposity is significantly reduced in obese mice with BIX/βCD oral treatment.•BIX & BIX/βCD reversed peripheral resistance to insulin in high-fat fed obese mice.•BIX/βCD oral treatment result in a reduction of CHT, and TG, and the increase of HDL-C.•Decreased hepatic steatosis was showed with the BIX/βCD oral treatment. Associations between obesity, diabetes type II, and steatosis have long been recognized. However, a pharmacotherapy that acts in a multifactorial manner controlling the interactions between these conditions is not available. A variety of natural plants, functional fatty acids, and other natural dietary compounds have been used in various anti-obesity products. We investigated the effects of oral administration of an antioxidant carotenoid pigment Bixin and Bixin: β-Cyclodextrin in an obese murine model. C57BL/6 male mice (4–5 weeks) received standard diet (2.18 kcal per 1 g) (CT) and high-fat diet (4.38 kcal per 1 g) (CT/OB, BIX and BIX/βCD) (n = 10 per group). After 16 weeks, the BIX and BIX/βCD were treated by gavage (100 μL day-1) for six weeks, with water (CT and CT/OB groups) and (50 mg kg-1 day-1), Bixin (BIX group) or Bix: β-CD (BIX/βCD). Body weight, Lee's Index, adiposity, CHT, TG, CHT/HDL-c, glucose levels (metabolic markers) and, liver markers (AST and ALT) were determined. All metabolic and liver parameters exhibited down-regulation after oral administration of BIX and BIX/βCD. Particularly relevant was Lee’s Index and adiposity in BIX- and BIX/βCD-treated groups (339.18 g/cm -BIX and 327.58 g/cm -BIX/βCD vs. 360.68 g/cm -CT/OB animals), this finds associated with the insulin sensitivity test, showed a clear association between reduction of adipose tissue and decrease of peripherical insulin resistant. In conclusion, our study suggested that the oral administration of the Bixin and Bix: β-CD inclusion compound improved the metabolic parameters evaluate in obese mice, being more palatable and hepatoprotective.